Strategic partnerships ChromaCode actively pursues collaborations with medical institutions and diagnostic laboratories, including partnerships with Department of Pathology at Phramongkutklao College of Medicine and Medical College of Georgia. This indicates warm channels for co development, pilot programs, and early access offers for their NSCLC assay and rapid biomarker testing.

Oncology focus The company has launched an NSCLC assay and an oncology testing kit, signaling a strong emphasis on cancer diagnostics. Sales opportunities exist in hospital systems, cancer centers, and clinical labs seeking actionable, rapid dPCR based tests for lung cancer biomarkers.

Cloud analytics ChromaCode Cloud 6.1 release demonstrates an emphasis on cloud based data analysis and scalable workflows. This suggests sales potential for institutions needing integrated data management, remote analysis, and secure compliance to support high throughput diagnostics.

Affordable innovation Positioned as providing high performance biochemical assay enrichment at very low cost, there is a compelling value proposition for budget conscious labs and contract research organizations seeking performance gains without broad capital expenditure.

Growth potential With a funding level of 98M and revenue in the low to mid millions, ChromaCode appears to be in growth mode and could benefit from strategic OEM partnerships, channel alliances, and pilot programs with mid to large diagnostics players to accelerate market penetration.